"Doudna's Aclaris CEO Steps Down, Secures $114M Liver Disorder Deal with Genevant"
TL;DR
Jennifer Doudna's lab published a study detailing how antibody fragments can target virus-like particles with gene editing machinery to T cells, co-founding genetic medicine delivery startup Azalea Therapeutics, which has raised $10 million.
Topics:healthbiotechnology#azalea-therapeutics#biotechnology#gene-editing#genetic-medicine#jennifer-doudna#t-cells
Want the full story? Read the original reporting
Read on Endpoints News